- Miromatrix Medical ( NASDAQ: MIRO ) said it has received a new patent from the U.S. Patent and Trademark Office for its perfusion decellularization and recellularization technology.
- The patent number 11,414,644 titled 'Methods of Recellularizing a Tissue or Organ for Improved Transplantability' covers the revascularization of decellularized organs and tissues which include all types of organs including liver, lung, kidney, and heart.
- The new patent expands the company's patent portfolio covering the bioengineering of transplantable organs, Miromatrix said in an Aug. 25 press release.
For further details see:
Miromatrix gets US patent for recellularizing technology for use in organ transplant